

List of Externally funded Ongoing Studies

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
1	Anatomy	J.Suganthy	3.0	Studies on antigen presenting cell in human reproductive organs	ICMR
2	Biochemistry	Joe Varghese	3.0	Is activation of haem oxygenase-1 involved in iron accumulation in alcoholic liver disease.	DBT
3	Biochemistry	Molly Jacob	3.0	How does inflammation affect the handling of iron in the body.	DBT
4	Biochemistry	Molly Jacob	3.0	Pathogenesis of nonsteroidal anti-inflammatory drug (NSAID) induced renal damage.	DST
5	Biochemistry	Molly Jacob	1.8	Effect of hepcidin on iron transport molecules.	CMC-NCBS Collaboration
6	Biochemistry	Premila Abraham	3.0	Identification of nitrated proteins that may play a critical role in the pathogenesis of methotrexate induced small intestinal damage in the rat and possible ways to prevent the damage by the administration of nitric oxide synthase inhibitors	CSIR
7	Biochemistry	Premila Abraham	3.0	A study on the possible role of oxidative stress and NFkB pathway in the pathogenesis of Anti-HIV drug (indinavir) induced renal damage in the rats and possible ways to prevent the damage.	CSIR
8	Bio-Engineering	George Mathew	3.0	Virtually reality based minimally invasive surgical simulator (VR based surgical simulator)	Information technology ministry of communications
9	Bio-Engineering	Suresh Devasahayam	3.0	Implanted neural interfaces and control schemes for artificial hand control.	DBT
10	Bio-Engineering	Suresh Devasahayam	3.0	Enhanced artificial hand control.	DBT
11	Biostatistics	L. Jeyaseelan	2.0	Pivotal study to evaluate the immunogenicity and safety of a measles vaccine given by aerosolized inhalation: randomized controlled trial	WHO, Geneva
12	Cardiology	Paul.V.George	2.0	Efficacy of stem cell in improvement of left ventricular function in patients with acute myocardial infarction.	DBT

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
13	Cardiology I	Jacob Jose/Kuryan George	1.0	A study of cardiovascular disease related lifestyle and their behavioural determinants among different population groups in India.	ICMR
14	CHAD	Anuradha Bose	0.10	Randomised , double blind, placebo controlled trial to evaluate the safety and immunogenicity of peru 15 vaccine given simulatenously with measles in healthy Indian infants	International vaccine institute,seoul, Korea
15	CHAD	Muniraj	2.3	Repeat zonal level tuberculin survey for estimating annual risk of tuberculosis infection (South Zone)	Central TB Division Via. National Tuberculosis
16	CHAD	Reginald George Alex	1.0	Collection of clinical sample sets: sputum, blood and urine, from patients potentially infected with Mycobacterium Tuberculosis	Agada Health Sciences Pvt. Ltd, Chennai
17	CHAD	Vinod Joseph Abraham	3.0	Nodal Coordinating Unit of Satellite Centres for RF/RHD Control at CMC.	ICMR
18	CHAD	Vinod Joseph Abraham	3.0	Comprehensive approaches to understand streptococcal diseases and their sequelae to develop innovative strategies for diagnosis, therapy, prevention and control.	European Union
19	Child Health I	Leni Grace Mathew	0.6	Acute liver failure - a retrospective review.	GlaxoSmithKline
20	Child Health I	Valsan Philip Verghese	1.0	A Phase III, open, randomized, controlled primary vaccination study to demonstrate the non-inferiority of GSK Biologicals' meningococcal serogroup ACWY conjugate vaccine (GSK134612, MenACWY-TI) given intramuscularly versus Mencevax TM ACWY given subcutaneo	GlaxoSmithKline
21	Child Health I	Valsan Philip Verghese	2.0	A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in India.	Wyeth Pharmaceuticals Inc.
22	Child Health I	Valsan Philip Verghese	1.0	Effectiveness of Haemophilus influenzae type b (Hib) Vaccine in Vellore, India: a case control study	Johns Hopkins University
23	Child Health I	Valsan Philip Verghese	1.0	A Phase III, randomized, single blind, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) biologicals' 10-valent pneumococcal conjugate vaccine as a 3-dose primary immunization course at 6, 10 and 14 weeks of	GlaxoSmithKline

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
24	Clinical Epidemiology Unit	Kurien Thomas		Invasive bacterial infection surveillance (ICMR-IBIS) in India.	INCLLEN
25	Clinical Epidemiology Unit	Kurien Thomas	2.0	South Asian pneumococcal network alliance (SAPNA).	INCLLEN
26	Clinical Immunology and Rheumatology	Debashish Danda	1.0	Effectiveness of Osteoporosis support in Indian patients of osteoporosis on Risedronate.	Aventis
27	Clinical Immunology and Rheumatology	Debashish Danda	0.4	Observational trial on the value of diagnostic criteria in the diagnosis of spinal spondyloarthropathies in patients with chronic low back pain	Schering-plough Research institute
28	Clinical Immunology and Rheumatology	Debashish Danda	5.0.	A randomized, phase 3, controlled, double, blind, parallel-group, multicentre study to evaluate the safety and efficacy of rituximab in combination with methotrexate (Mtx) compared to Mtx alone, in methotrexate naïve patients with active rheumatoid arthri	Roche Sample Repository Research Project
29	Clinical Immunology and Rheumatology	Debashish Danda		A randomized, phase 3, controlled, double blind, parallel group, multicenter study to evaluate the safety and efficacy of Rituximab in combination with Methotrexae (MTX) alone, in Methotrexate-naïve patients with active rheumatoid arthritis.	Siro Clinpharm Pvt. Ltd.
30	Clinical Pathology	Dolly Daniel	2.0	Training laboratory personnel for diagnosis of haemophilia in India.	Baylor Health Care
31	Endocrinology	M.S. Seshadri	6.0	Protocol MK-0822: A Phase III Randomized, placebo – controlled clinical trial to assess the safety and efficacy of Odanacatib (MK-0822) to reduce the risk of fracture in Osteoporotic postmenopausal women treated with Vitamin D and Calcium	Clinigene International Private Limited
32	Endocrinology	M.S. Seshadri	5.0	Effects of Arzoxifene on Vertebral fracture incidence and on invasive breast cancer incidence in postmenopausal women with osteoporosis or with low bone density.	Quintiles
33	Endocrinology	Nihal Thomas	5.0	A randomized, doubled-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal mo	Academic Alliance for Clinical Trials

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
34	Endocrinology	Nihal Thomas	Till July 2010	1) Insulin resistance assessed by the hyperinsulinemic euglycemic clamp technique. 2) Body composition as assessed by DEMA scanning and high resolution ultrasonography. 3) Skeletal muscle triglyceride content as assessed by H. Nuclear Magnetic Resonance	University of Copenhagen, Denmark
35	Endocrinology	Nihal Thomas	1.0	A Multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 trial to evaluate the safety and efficacy of Dapagliflozin in combination with thiazolidinedione therapy in subjects with type 2 diabetes who have	Bristol-Myer's Squibb
36	Endocrinology	Nihal Thomas	5.0	A randomized double – blind, placebo controlled study with a 2 * 2 factorial design to evaluate rosuvastatin and Candesartan + hydrochlorothiazide in men aged >55 years and women aged >65 years with one risk factor for cardiovascular disease such as smoking	PHRI, Canada
37	Endocrinology	Nihal Thomas	0.8	A 26 week randomized, controlled, open label, multicenter, multinational, three arm, treat to target trial comparing efficacy and safety of three different dosing regimens of either soluble insulin basal analogue (SIBA) or insulin glargine with or without	Novo Nordisk
38	Endocrinology	Nihal Thomas	2.0	A Phase 2 Randomized double blinded placebo and – active comparator controlled study to evaluate the safety and efficacy of MBX-102/JNJ-39659100 in patient with type 2 diabetes mellitus with inadequate control on Metformin monotherapy	Pharm-Olam International, Bangalore
39	Endocrinology	Nihal Thomas	4.0	A multicenter, multinational, randomized, 2x2 factorial design study to evaluate the effects of LANTUS TM (Insulin Glargine) versus standard care and omega-3 fatty acids versus placebo, in reducing cardiovascular morbidity and mortality in high risk people	Aventis
40	Endocrinology	Nihal Thomas	2.0	A multicenter randomized, double-blind, phase 3b trial to evaluate the efficacy and safety of saxagliptin added to insulin monotherapy or to insulin in combination in subjects with type 2 diabetes who have inadequate glycemic control on insulin alone or on	Bristol-Myer's Squibb
41	Endocrinology	Nihal Thomas	1.0	A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR110322 (SYR-322) when used in combination with a Sulfonylurea in subjects with type 2 diabetes", protocol number SYR-322-MET 008 entitled "A multi	PPD Pharmaceutical Development (I) Pvt. Ltd.
42	Endocrinology	Nihal Thomas	1.4	A multicenter, randomized, double-blind, study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes	Novartis

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
43	ENT I	Anand Job		Deafness prevention and rehabilitation programme.	CBM International
44	ENT I	Anand Job	1.0	Development, implementation and evaluation of a hearing aid service delivery model using Community Hearing Workers.	WHO, Geneva
45	ENT III	Achamma Balraj	1.0	Hospital based universal screening and rehabilitation of neonatal hearing loss	ICMR
46	ENT III	Rupa Vedantam	3.0	Characterization of Pneumococcal serotypes that colonise that nasopharynx of Indian infants and their role as a risk factor for acute suppurative otitis media	DST
47	GI Sciences	Anna B Pulimood		DST-FIST 2008	DST
48	GI Sciences	Anup Ramachandran	3.0	Cardiovascular complications in liver cirrhosis: Role of nitric oxide and mitochondria.	DBT
49	GI Sciences	Anup Ramachandran	2.0	Nitric oxide in organophosphate poisoning - sources, targets and consequences.	South Asian Clinical Toxicology Research
50	GI Sciences	Anup Ramachandran	2.0	Pathophysiological mechanisms in Oduvanthalai poisoning.	South Asian Clinical Toxicology Research
51	GI Sciences	B.S. Ramakrishna	3.0	Esterified starch and oral rehydration solution as a treatment for acute infectious diarrhoea.	DBT
52	GI Sciences	B.S. Ramakrishna	3.0	Analysis of NOD2 gene defects in Indian patients with Crohn's disease	DST
53	GI Sciences	B.S. Ramakrishna	3.0	Metagenomic study of the faecal anaerobic bacterial flora in healthy rural South Indian Subjects	DBT
54	GI Sciences	B.S. Ramakrishna	3.0	A multi-centric study on treatment of abdominal tuberculosis (intestinal or peritoneal): A randomized controlled trial to compare the 6 months of cat I treatment with 9 months of Cat I treatment (extension for 3 months) in abdominal tuberculosis under the	Revised National Tuberculosis Control Programme
55	GI Sciences	B.S. Ramakrishna	2.0	Planning for the delivery of a more effective oral rehydration solution to improve diarrhea control worldwide	Bill and Melinda Gates Foundation

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
56	GI Sciences	B.S. Ramakrishna	1.0	Evaluation of Starplus modified starches for anti-diarrhoeal activity in an animal whole gut perfusion model.	CSIRO, Australia.
57	GI Sciences	B.S. Ramakrishna	1.0	Effect of yoghurt containing bifidobacterium lactis BB-12 on stool frequency and consistency and fecal microbiota in healthy adult volunteers	Chr Hansen
58	GI Sciences	B.S. Ramakrishna	1.0	A comparative study of inflammation bowel disease in India and the United States to assess environmental risk factors and gut flora	Crohn's and Colitis foundation of America
59	GI Sciences	B.S. Ramakrishna	2.0	Development of the intestinal bacterial flora in the neonate in South India: A molecular analysis	ICMR
60	GI Sciences	C.E. Eapen	3.0	Genotype phenotype correlation in Wilson's disease within families.	DST
61	GI Sciences	C.E. Eapen	3.0	Characterization of Wilson disease protein in human carcinoma cell lines and ACCC2 yeast strain".	DST
62	GI Sciences	C.E. Eapen	3.0	Genetic studies in Wilson's Disease.	DST
63	GI Sciences	C.E. Eapen	3.0	A comparative study of chronic hepatitis B subjects treated with Entecavir plus Tenofovir combination therapy vs. Entecavir monotherapy in Adults who are treatment-naïve to nucleosides and nucleosides: The BE-LOW study	Bristol-Myer's Squibb
64	GI Sciences	Gagandeep Kang	3.0	Characterization of human caliciviruses from India and expression of recombinant capsid protein in insect proteins in insect cells using the baculovirus system.	DST
65	GI Sciences	Gagandeep Kang	3.0	Establishment of the core vaccine research unit	DBT
66	GI Sciences	Gagandeep Kang	3.0	Hospital-based randomized control trial of racecadotril in acute diarrhoeal disease in children 6 months to 5 years of age	Swedish International Development Agency
67	GI Sciences	Gagandeep Kang	5.0 (extended)	Correlates of protection against viral gastroenteritis in children in Vellore, India.	Wellcome Trust, London
68	GI Sciences	Gagandeep Kang	5.0.	Multi-disciplinary research training in enteric infections.	NIH

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
69	GI Sciences	Gagandeep Kang	2.0	Impact of demographic and social change on gastroenteric viral infections	British Council under UK India Educational and
70	GI Sciences	Gagandeep Kang	5.0	Immune Response to Cryptosporidiosis in a Birth Cohort of Children of South India	NIH
71	GI Sciences	Gagandeep Kang	3.0	Production and delivery of antibody fragments against pathogens by lactobacilli.	European Union
72	GI Sciences	Gagandeep Kang	3.0	Study of risk factors for malnutrition using molecular and genomic tools	National Institutes of Health (Bill & Melinda Gates)
73	GI Sciences	Gagandeep Kang	4.0	Transmission dynamics of cryptosporidial infections in India.	NIH
74	GI Sciences	Gagandeep Kang	0.6	Phase I/II, randomized double-blind, placebo-controlled, dosage selection study to evaluate the safety, tolerability and immunogenicity of a 3-dose series of live attenuated tetravalent (G1-G4) Bovine Human Reassortant Rotavirus Vaccine (BRV-TV) administ	Shantha Biotechnics Ltd.
75	GI Sciences	Gagandeep Kang	3.0	Fut2 and ABO gene polymorphisms in determination of susceptibility to noroviral infections.	ICMR
76	GI Sciences	Sitara Swarna Rao	3.0	Investigation of TLR mediated innate immune response to Cryptosporidium parvum in human intestinal epithelial cell lines using sRNA based post transcriptional silencing.	DBT
77	GI Sciences	Sitara Swarna Rao	3.0	Cryptosporidial species Cgp40/14 polymorphisms and oocyst burden associated with diarrhea in HIV infected patients in south India	ICMR
78	GI Sciences	Sitara Swarna Rao	2.0	Genetic susceptibility and innate immunity to cryptosporidium infections in childhood - A candidate gene approach	ICMR
79	GI Sciences	Sumita Danda	3.0	Prevalence of connexin - 26 gene mutations in patients with congenital sensorineural hearing loss and correlation with their audiological profile.	ICMR
80	Haematology	Alok Srivastava	5.0	DBT Programme support in Molecular Haematology	DBT

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
81	Haematology	Alok Srivastava	2.0	Evaluating phenotypic heterogeneity in severe haemophilia	Bayer Healthcare
82	Haematology	Alok Srivastava	1.0	An open label, single arm study to evaluate the efficacy and safety of Rituximab in CD20 positive diffuse large B cell lymphoma when given along with CHOP chemotherapy.	Dr. Reddy's Laboratories
83	Haematology	Alok Srivastava	5.0.	Musculoskeletal function in hemophilia in developing countries.	Bayer Healthcare
84	Haematology	Alok Srivastava	1.0	An international, multicentre, non-randomised open-labeled study to evaluate the efficacy of lower dose dexamethasone / thalidomide and higher frequency ZOMETA TM in the treatment of previously untreated patients with multiple myeloma.	Novartis
85	Haematology	Alok Srivastava	2.0	Training nurses to provide hemophilia care: A new model for India.	Bayer Healthcare
86	Haematology	Alok Srivastava	2.0	Novel molecular mechanism leading to a haemophilia A phenotype	Bayer Healthcare
87	Haematology	Alok Srivastava	1.0	Assessment of an anti-TFPI aptamer:ARC 19499 in correcting the abnormal hemostasis of blood from patients with hemophilia and evaluation of its concentration-effect relationship	Archemix Corporation
88	Haematology	Alok Srivastava		Novoseven in critical bleeding	Novo Nordisk
89	Haematology	Biju George	1.0	Evaluation of clinical efficacy, safety and tolerability of Thymoglobuline as primary therapy of aplastic anemia	GENZYME Corporation
90	Haematology	Eunice Sindhuvi	3.0	Molecular and functional evaluation of gene involved in iron absorption, transport and storage in the context of iron deficiency	DBT
91	Haematology	Eunice Sindhuvi	3.0	Transcriptional and Translational Process of Beta E Gene	DBT
92	Haematology	Jayandhran G.Rao	3.0	Molecular Genetics of Hereditary Rare Bleeding disorders in the Indian Population	DBT

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
93	Haematology	Poonkuzhali B	5.0	Pharmacogenetics of Cytarabine and Daunorubicin	DBT
94	Haematology	Poonkuzhali B	5.0	Mechanisms of Imatinib Resistance in CML	DBT
95	Haematology	Shaji R V	5.0	Molecular Mechanism of Human Globin Gene Regulation	DBT
96	Haematology	Shaji R V		Molecular Basis of Fanconi Anemia in Indian Population	DBT
97	Haematology	Vikram Mathews	3.9	Evaluation of cellular and molecular mechanisms of resistance to arsenic trioxide in acute promyelocytic leukemia.	DBT
98	Haematology	Vikram Mathews	5.0	Evaluation of Molecular Marker in Patients with AML	DBT
99	Haematology	Vikram Mathews	5.0	An open label, randomized, multicenter Phase III trial of Dasatinib (SPRYCEL) vs. Standard Dose Imatinib (400 mg) in the treatment of subjects with newly diagnosed Chronic Phase Ph+ve CML	Bristol-Myer's Squibb
100	Haematology	Vikram Mathews	2.0	Prevalence of inhibitors in patients with severe hemophilia A in India: Impact of environmental and genetic factors on prevalence.	Bayer Healthcare
101	Haematology	Vikram Mathews	6.9	A phase 1/2 study of SKI-606 in Philadelphia Chromosome Positive Leukemias.	Wyeth Pharmaceuticals Inc.
102	M.H.C.	K.S.Jacob	4.0	ICMR Taskforce project on suicide behaviour in Vellore.	ICMR
103	M.H.C.	Prathap Tharyan	5.0	An advance centre for research and training evidence based health centre at CMC, Vellore.	ICMR
104	M.H.C.	Prathap Tharyan	6.0	Effective Health Care Alliance Programme (EHCAP)	Liverpool School Tropical Medicine
105	M.H.C.	Prathap Tharyan	1.0	Production of systematic reviews for the Cochrane Schizophrenia Group.	Department of Health, University of Leeds

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
106	Medical Genetics	Sumita Danda	4.0	GZGD02507- A phase 3, randomized, double blind, placebo controlled, multi-centre study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type-1	GENZYME Corporation
107	Medical Oncology	Raju Titus Chacko	2.0	Multicentre, randomized, double-blinded, phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIb/IV or recurrent non-small lung	Boehringer Ingelheim Korea Ltd
108	Medical Oncology	Raju Titus Chacko	0.8	An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre study to assess the efficacy of ZD6474 (ZACTIMATM) versus placebo in subjects with unresectable, locally advanced or metastatic medullary thyroid cancer	AstraZeneca Pharma
109	Medical Oncology	Raju Titus Chacko	4.6	An open label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (Q3W) in patients with locally advanced and/or metastatic breast cancer and Roche sample repository research project in assoc	Hoffman-LaRoche Inc.
110	Medical Oncology	Raju Titus Chacko	1.9	A randomized, open-label, multicenter, phase 3 study of epoetin alfa plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer receiving first-line standard chemotherapy.	PAREXEL International Limited
111	Medical Oncology	Raju Titus Chacko	3.0	A phase 2, multicenter, open label randomized trial of AMG 706 or Bevacizumab in combination with Paclitaxel and Carboplatin for Advanced non-squamous non-small cell lung cancer	Amgen Inc. California
112	Medical Oncology	Raju Titus Chacko	2.0	A Phase III, randomized, double blind, placebo controlled study to assess the efficacy and safety of 10mg ZD4054 versus placebo in combination with Docetaxel in comparison with Docetaxel in patients with metastatic hormone-resistant prostate cancer	ICON Clinical Research India Pvt. Ltd.
113	Medical Oncology	Raju Titus Chacko	2.0	Randomized study of Larotaxel with Cisplatin (LC) versus Gemcitabine with Cisplatin (GC) in the First Line Treatment of locally advanced / Metastatic urothelial tract or bladder cancer	Sanofi-Synthelabo (India) Ltd.
114	Medical Oncology	Raju Titus Chacko	2.0	A Phase II Biomarker Identification Trial for Erlotinib (Tarceva) in patients with advanced pancreatic carcinoma (MARK Study)	Covance India Pharmaceuticals Service
115	Medicine I & Infectious Diseases	George M Varghese	1.0	EU-CORESM - European CUBICINR outcome registry and experience for the treatment of serious gram positive infections: A retrospective post marketing surveillance of Daptomycin	Novartis

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
116	Medicine I & Infectious Diseases	George M Varghese	1.0	Genotyping or orientia tsutsugamushi from patients with scrub typhus	International society of infectious diseases
117	Medicine I & Infectious Diseases	Dilip Mathai		National vector borne disease control study.	National Centre for Tropical Medicine and Imported
118	Medicine I & Infectious Diseases	Dilip Mathai	3.0	Clinico-epidemiologic and molecular characterization of extended spectrum beta lactamase (ESBL) producing klebsiella spp. E.coli & enterobacter spp causing nosocomial and community infections.	ICMR
119	Medicine I & Infectious Diseases	Dilip Mathai	1.0	Incidence of HPV infection among HIV seropositive MSM in India.	ICMR
120	Medicine I & Infectious Diseases	Dilip Mathai		India Quality Healthcare Improvement Initiative (India-Sentry Programme)	JMI Laboratories, USA.
121	Medicine I & Infectious Diseases	Dilip Mathai	3.0	A double blind randomized, parallel, placebo controlled study to determine the efficacy of addition of Vitamin D to conventional anti TB therapy on time to smear conversion.	Bayer Healthcare
122	Medicine I & Infectious Diseases	Dilip Mathai	1.0	A randomized, double-blind, multicenter, placebo-controlled phase III superiority study to assess the safety and efficacy of topical retapamulin ointment, 1% versus placebo ointment applied twice daily for 5 days in the treatment of adult and paediatric s	Glaxo Smithkline & Paraxel International Ltd
123	Medicine II	Kurien Thomas	3.0	Invasive pneumococcal disease in adults in South Asia.	Johns Hopkins University
124	Microbiology	Joy Sarojini Michael	1.0	Xpert MTB/Rif demonstration study for molecular diagnosis of tuberculosis	Foundation of Innovative Diagnostics (FIND), New
125	Neurochemistry	Anna Oommen	2.0	Muscle paralysis in acute organophosphate poisoning: Role of nitric oxide and mitochondrial calcium handling.	DBT
126	Neurochemistry	Anna Oommen	3.0	The role of NF- κ B in muscle wasting of limb girdle muscular dystrophy 2A	ICMR
127	Neurochemistry	Anna Oommen	3.0	Mitochondrial bioenergetics and neuromuscular weakness of acute organophosphate poisoning.	Defence Research & Development Organization

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
128	Neurological Sciences	Srinivasa Babu	3.0	A multi-disciplinary, systems-level investigation into neurobiology of Parkinson's disease	DBT
129	Neurology	Srinivasa Babu	3.0	Cellular mechanisms of temporal lobe epilepsy: in vitro studies in the human brain and animal models	DBT
130	Neurology	V.Rajshekhar	4.0	Impact assessment and control of cysticercosis in the Indian subcontinent.	Belgium Cysticercosis project
131	O.G. I	Jiji Mathew	6.0	International study of caesar trial.	University of Oxford
132	O.G. III	Annie Regi	1.0	Chlamydia trachomatis: A study of the prevalence of disease in pregnant women and rates of transmission to the infant in Vellore, India	Sub-Contract from the Cincinnati Childrens'
133	Orthopaedics III	Boopalan	3.0	Regeneration of cartilage lesions using growth factor, of TGF b family (BMP 2) in rabbit knees.	DST
134	Orthopaedics III	Boopalan	1.0	Autologous versus allogenic chondrocyte transplantation for treatment of articular cartilage defects in rabbit knees.	DBT
135	Orthopaedics III	Vrisha Madhuri	3.0	Efficacy of cultured autologous chondrocyte transplantation in the treatment of physeal injury in goats.	DBT
136	Pulmonary Medicine	D.J.Christopher	1.0	Evaluation of efficacy and tolerability of deflazacort versus prednisolone in the treatment of OPD exacerbation of bronchial asthma.	Macleods Pharmaceuticals
137	Pulmonary Medicine	D.J.Christopher	5.0	Validation of interferon -gamma assay for the diagnosis of tuberculosis infection in health care workers	McGill University, Canada
138	Pulmonary Medicine	D.J.Christopher	1.0	A randomized placebo controlled efficacy and safety study of 1 year treatment duration with high and medium dose inhaled mometasone furoate / formoterol combination formulation compared with formoterol and high dose inhaled mometasone furoate monotherapy	Quintiles
139	Pulmonary Medicine	D.J.Christopher	1.0	A randomized, double-blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]) deliver	Quintiles

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
140	Pulmonary Medicine	D.J.Christopher	0.3	A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 µg o.d.) via a SDDPI in patients with moderate to severe COPD, using salmeterol (50 µg b.i.d) as an active compar	Novartis
141	Pulmonary Medicine	D.J.Christopher	1.0	a phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150µg o.d. vs inhaled tiotropium 18 µg o.d on lung function, rate of exacerbations and related outcom	Novartis
142	Radiology	Sridhar Gibikote / Shyam Kumar	1.0	Measurement of properties of ultrasound for assessment of haemophilic arthropathy with MRI correlation.	Bayer Healthcare
143	Radiotherapy	Paul Ravindran	3.0	Investigation of radiation dose to patient during image guidance in radiotherapy	Department of Atomic Energy
144	Radiotherapy II	Subhashini John	1.1	A randomized, doubled-blind, multicenter study of denosumab compared with Zoledronic Acid (Zometa) in the Treatment of Bone metastases in subjects with advanced breast cancer.	Amgen Inc. California
145	Radiotherapy II	Subhashini John	1.0	Nanobiotechnology in anticancer therapy and development of nanoparticle based drug delivery system of Temozolamide for central nervous system tumours.	CMC-NCBS Collaboration
146	Radiotherapy II	Subhashini John	0.6	A multicenter, randomized, open label, two period, two treatment , two way crossover, bioequivalence study comparing capecitabine tablets 500 mg (Manufactured by Intas Pharmaceuticals Ltd., India) to the reference listed drug XELODA 500mg tablets (Manufac	INTAS Pharmaceuticals Ltd, &Roche Pharma
147	Radiotherapy II	Subhashini John	3.7	A randomized, double blind, parallel group, multicentre, phase III study comparing the efficacy and tolerability of Fulvestrant (FALSODEX fm) 500 mg with Fulvestrant (FALSODEX fm) 250 mg in Postmenopausal women with Oestrogen Receptor positive advanced br	Quintiles
148	Radiotherapy II	Subhashini John	5.0	A prospective observational longitudinal study to evaluate molecular markers for disease staging and clinical response in breast carcinoma.	Triesta Sciences (I) Pvt. Ltd. Bangalore
149	Radiotherapy II	Subhashini John	2.0	An open label, multicenter phase I/II study of selective cycling dependent kinase inhibitor P276-00 in combination with radiation in subjects with recurrent and/or locally advanced squamous cell carcinoma of head and neck	Primal Life Sciences limited, Mumbai

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
150	Radiotherapy II	Subhashini John	2.0	An open label prospective multicentric study to evaluate the safety and efficacy of BIOMAb-EGFR TM (Nimotuzumab) as induction and as induction and maintenance therapy in combination with radiotherapy plus temozolomide (Concomitant & Adjuvant) in Indian pat	Clinigene International Private Limited
151	Radiotherapy II	Subhashini John	3.0	Protocol: AP23573-07-302: A pivotal trial to determine the efficacy and safety of AP23573 when administered as maintenance therapy to patients with Metastatic soft-tissue or bone sarcomas.	Aiad Pharmaceuticals, Inc.
152	Radiotherapy II	Subhashini John	2.0	A phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non small cell lung cancer who have failed two or more prior treatment regimens	Agennix Incorporated
153	Radiotherapy II	Subhashini John	3.0	Protocol EFC 10339 - International randomized study to evaluate the addition of Docetaxel to the combination of Cisplatin-5 fluorouracil (TCF) vs. Cisplatin-5 fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and ado	Sanofi-Synthelabo (India) Ltd.
154	RUHSA	Rita Isaac	5.0	Impact of intestinal dysfunction on retroviral therapy in India.	NIH
155	RUHSA	Rita Isaac		RUHSA Research project - Dr. Madelon Finkel	Weill Medical College of Cornell University, USA.
156	RUHSA	Rita Isaac	0.5	Survey on assessing patient costs due to tuberculosis.	Canadian Institute for Health Research
157	SICU	Nagamani Sen	1.0	Prospective study on rate surveillance, risk factors process and costs of Nosocomial infections in intensive care units (ICU).	Baxter Healthcare
158	Stemcell	M. Diana M.E. Otto	2.0	Role of semaphorins and respective receptors in mesenchymal stem cells	DBT
159	Stemcell	Prithi Rajan	2.0	Definition of the role of ATM kinase in cellular differentiation and cancer	DBT
160	Virology	Asha Mary Abraham	3.0	Multi-site monitoring of human influenza in India - Phase I.	ICMR
161	Virology	Mahesh Moorthy	1.0	A multiplex real time PCR approach to determine viral etiology of acute lower respiratory infections in children in a tertiary hospital in Tamil Nadu	ICMR

S.No.	Department	NAME OF THE PI	Duration	Title of the Project	Funding Agency
162	Virology	Priya Abraham	2.0	An investigation into certain genetic and immunological (HLA), MBL2, TLRs & IFN- γ gene SNAPs) factors that influence the outcome of hepatitis B virus (HBV) infection in South Indian individuals.	DBT
163	Virology	Priya Abraham	2.0	A life course approach to the aetiology of head and neck cancer: Hence life study	Canadian Institute for Health Research
164	Virology	Priya Abraham	3.0	Characterization of hepatitis B virus drug resistance in Indian subcontinent patients	ICMR
165	Virology	Rajesh Kannangai	3.0	A study on the virological and immunological aspects associated with opportunistic viral infections in HIV-1 infected individuals in India (South).	DBT
166	Virology	Rajesh Kannangai	3.0	Human immunodeficiency virus type 1 reverse transcriptase and protease gene mutation: An observational and prediction study on antiretroviral interactions	ICMR